145 related articles for article (PubMed ID: 12741452)
1. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
Damiano A; Siddique R; Xu X; Johanson J; Sloan S
Dig Dis Sci; 2003 Apr; 48(4):657-62. PubMed ID: 12741452
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
Kahrilas PJ; Miner P; Johanson J; Mao L; Jokubaitis L; Sloan S
Dig Dis Sci; 2005 Nov; 50(11):2009-18. PubMed ID: 16240208
[TBL] [Abstract][Full Text] [Related]
4. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
Damiano A; Handley K; Adler E; Siddique R; Bhattacharyja A
Dig Dis Sci; 2002 Jul; 47(7):1530-7. PubMed ID: 12141813
[TBL] [Abstract][Full Text] [Related]
5. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
[TBL] [Abstract][Full Text] [Related]
6. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
[TBL] [Abstract][Full Text] [Related]
7. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
[TBL] [Abstract][Full Text] [Related]
8. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Cloud ML; Enas N; Humphries TJ; Bassion S
Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rabeprazole once daily for acid-related disorders.
Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
Minushkin ON; Maslovskiĭ LV; Anikina NIu; Shuleshova AG
Eksp Klin Gastroenterol; 2005; (2):29-35. PubMed ID: 15932152
[No Abstract] [Full Text] [Related]
11. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
Ponce J; Argüello L; Bastida G; Ponce M; Ortiz V; Garrigues V
Dig Dis Sci; 2004 Jun; 49(6):931-6. PubMed ID: 15309880
[TBL] [Abstract][Full Text] [Related]
12. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.
Sloan S
Am J Gastroenterol; 2003 Mar; 98(3 Suppl):S49-55. PubMed ID: 12644031
[TBL] [Abstract][Full Text] [Related]
13. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Caos A; Breiter J; Perdomo C; Barth J
Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
[TBL] [Abstract][Full Text] [Related]
14. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
15. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
[TBL] [Abstract][Full Text] [Related]
16. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
Lim PW; Goh KL
J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
[TBL] [Abstract][Full Text] [Related]
17. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
18. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Farley A; Wruble LD; Humphries TJ
Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
[TBL] [Abstract][Full Text] [Related]
19. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
